Preempting all state regulation in the absence of federal action would leave a dangerous vacuum, further undermining public confidence in these technologies.
At this inflection point, the choice is not between speed and safety but between ungoverned acceleration and a calculated momentum that allows our strategic AI advantage to be both sustained and secured.
Improved detection could strengthen deterrence, but only if accompanying hazards—automation bias, model hallucinations, exploitable software vulnerabilities, and the risk of eroding assured second‑strike capability—are well managed.
A dedicated and properly resourced national entity is essential for supporting the development of safe, secure, and trustworthy AI to drive widespread adoption, by providing sustained, independent technical assessments and emergency coordination.
Congress should establish a new grant program, coordinated by the Cybersecurity and Infrastructure Security Agency, to assist state and local governments in addressing AI challenges.
If AI systems are not always reliable and secure, this could inhibit their adoption, especially in high-stakes scenarios, potentially compromising American AI leadership.
To secure global adoption of U.S. AI technology and ensure America’s workforce can fully leverage advanced AI, the federal government should take a strategic and coordinated approach to support AI assurance and security R&D.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.
It’s paramount to balance both innovation capabilities and risk as we work towards ensuring that the U.S. bioeconomy is a priority area for both the Nation and for National Security.
The Federation of American Scientists supports the National Security Commission on Emerging Biotechnology’s Final Report and the Recommendations contained within it.
The U.S. should create a new non-governmental Innovation Accelerator modeled after the successful In-Q-Tel program to invest in small and mid-cap companies creating technologies that address critical needs of the United States.